BR112022018136A2 - Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização - Google Patents

Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização

Info

Publication number
BR112022018136A2
BR112022018136A2 BR112022018136A BR112022018136A BR112022018136A2 BR 112022018136 A2 BR112022018136 A2 BR 112022018136A2 BR 112022018136 A BR112022018136 A BR 112022018136A BR 112022018136 A BR112022018136 A BR 112022018136A BR 112022018136 A2 BR112022018136 A2 BR 112022018136A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
hemorrhage
thrombolytic drug
reperfusion injuries
Prior art date
Application number
BR112022018136A
Other languages
English (en)
Portuguese (pt)
Inventor
Joo Gwag Byoung
San An Chun
yu jin Jing
Ig Cho Sung
Zhu Fangmeng
Xu Xinliang
Zhan Weiqiang
Liu Fuxin
Won Soon-Mi
Original Assignee
Gnt Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnt Pharma Co Ltd filed Critical Gnt Pharma Co Ltd
Publication of BR112022018136A2 publication Critical patent/BR112022018136A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022018136A 2020-03-11 2021-03-10 Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização BR112022018136A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (1)

Publication Number Publication Date
BR112022018136A2 true BR112022018136A2 (pt) 2022-10-25

Family

ID=77665492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018136A BR112022018136A2 (pt) 2020-03-11 2021-03-10 Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização

Country Status (12)

Country Link
US (3) US11826329B2 (cg-RX-API-DMAC7.html)
EP (1) EP4117648A4 (cg-RX-API-DMAC7.html)
JP (2) JP7870252B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230010187A (cg-RX-API-DMAC7.html)
CN (1) CN115515573A (cg-RX-API-DMAC7.html)
AU (1) AU2021233206A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018136A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174709A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014343A2 (cg-RX-API-DMAC7.html)
IL (2) IL296288B2 (cg-RX-API-DMAC7.html)
MX (2) MX2022011214A (cg-RX-API-DMAC7.html)
WO (1) WO2021181159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
US11826329B2 (en) 2020-03-11 2023-11-28 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100545745B1 (ko) * 2002-06-19 2006-01-24 주식회사 뉴로테크 테트라플루오로벤질 유도체 및 이를 함유하는 급성 및퇴행성 뇌신경계 질환의 예방 및 치료용 약학적 조성물
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
KR20060121721A (ko) * 2005-05-23 2006-11-29 주식회사 중외제약 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물
KR20060121768A (ko) * 2005-05-25 2006-11-29 주식회사 중외제약 테트라플루오로벤질 아닐린 유도체 및 이의 약학적으로허용가능한 염 화합물의 제조방법
KR101523345B1 (ko) * 2008-04-28 2015-05-28 주식회사 지엔티파마 재관류 손상의 치료 또는 예방용 약학 조성물
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
US11826329B2 (en) 2020-03-11 2023-11-28 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Also Published As

Publication number Publication date
IL296288B1 (en) 2024-02-01
CA3174709A1 (en) 2021-09-16
US20260027076A1 (en) 2026-01-29
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
JP7870252B2 (ja) 2026-06-04
IL296288A (en) 2022-11-01
CO2022014343A2 (es) 2023-02-16
JP2023517566A (ja) 2023-04-26
US20210283080A1 (en) 2021-09-16
CN115515573A (zh) 2022-12-23
IL309923A (en) 2024-03-01
IL296288B2 (en) 2024-06-01
US11826329B2 (en) 2023-11-28
MX2022011214A (es) 2022-10-07
AU2021233206A1 (en) 2022-10-06
WO2021181159A1 (en) 2021-09-16
JP2026082994A (ja) 2026-05-19
US20230390231A1 (en) 2023-12-07
KR20230010187A (ko) 2023-01-18
US12433861B2 (en) 2025-10-07
MX2025012439A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
MX2022011214A (es) Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion.
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
WO2008131941A1 (en) Treatment of movement disorders by a combined use of botulinum toxin and muscle stimulation
López-López et al. Application of cantharidin, podophyllotoxin, and salicylic acid in recalcitrant plantar warts. A preliminary study
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
Sarkaki et al. Therapeutic effects of resveratrol on ischemia–reperfusion injury in the nervous system
KR100951542B1 (ko) 방광 자극 및 과민성 방광을 치료하기 위한 약제학적 조성물
Aguilera-Roig et al. Tranexamic acid in orthopedic surgery
CR20250205A (es) Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus.
Zeng et al. Activation of inflammasomes and relevant modulators for the treatment of microglia-mediated neuroinflammation in ischemic stroke
AU2014210332B2 (en) Method of treating fibrosis in skeletal muscle tissue
RU2417765C2 (ru) Способ лечения подкожной гематомы, образовавшейся вследствие укуса животного
KR20160094345A (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
DeRossi et al. Efficacy of concurrent epidural administration of neostigmine and lidocaine for perineal analgesia in geldings
Sonune et al. Comparative study of ultrasound guided supra-scapular nerve block versus intra-articular steroid injection in frozen shoulder
Kurt et al. Effects of adding alfentanil or atracurium to lidocaine solution for intravenous regional anaesthesia
Viswanathan et al. Intraosseous regional antibiotic prophylaxis in total joint arthroplasty (TJA): Systematic review and meta-analysis
Su et al. Comparison between periarticular analgesia versus intraarticular injection for effectiveness and safety after total knee arthroplasty
CY1113544T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος
CA2785303A1 (en) Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual
WO2022007833A1 (zh) 一种组合物在治疗脑卒中的用途
Srinivasan et al. Ultrasound guided 4 in 1 block for managing postoperative pain in arthroscopic knee surgery
Jadhav et al. A prospective, multicentric study to determine the safety and effectiveness of fixed-dose combination of camylofin dihydrochloride and nimesulide in patients presenting with acute colicky abdominal pain in India
CZ2003957A3 (cs) Použití argininu při přípravě léků pro prevenci a léčení vedlejších účinků spojených s itravenózním podáním farmaceutických preparátů
Rachiele et al. Complication of Arterial Drug Injections: Treading Cautiously Beyond Primum Non-Nocere

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025026201-3 PROTOCOLO 870250109070 EM 27/11/2025 17:53.